Abstract
Glucagon-like peptide-1 (GLP-1) is a gut hormone that plays an important role in regulating glucose homeostasis by both its pancreatic and extrapancreatic activity. Defects of GLP-1 characterize type 2 diabetes as a primary or perhaps consequent phenomenon, resulting in inappropriately low insulin secretion after oral ingestion of nutrients. The discovery that cleavage by the ubiquitous enzyme dipeptidyl peptidase-IV (DPP-IV) is the primary route of GLP-1 metabolism formed the rationale behind the proposal to prevent degradation of endogenously released GLP-1 by DPP-IV inhibition as a novel approach to the management of type 2 diabetes. Enhanced insulin secretion as well as delayed gastric emptying, reduced glucagon secretion, and inhibited apoptosis of beta cells resulting from blockade of incretin degradation, have been proposed as the major actions of DPP-IV inhibitors as antidiabetic agents. Clinical studies to date indicate that DPP-IV inhibitors effectively ameliorate islet dysfunction and improve glucose control in patients with type 2 diabetes. They appear to have excellent therapeutic effectiveness as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. Their pharmacokinetic and pharmacodynamic profiles support once-daily dosing, with relatively few adverse effects.
Current Diabetes Reviews
Title: Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Volume: 5 Issue: 2
Author(s): Teresa Salvatore, Ornella Carbonara, Domenico Cozzolino, Roberto Torella and Ferdinando C. Sasso
Affiliation:
Abstract: Glucagon-like peptide-1 (GLP-1) is a gut hormone that plays an important role in regulating glucose homeostasis by both its pancreatic and extrapancreatic activity. Defects of GLP-1 characterize type 2 diabetes as a primary or perhaps consequent phenomenon, resulting in inappropriately low insulin secretion after oral ingestion of nutrients. The discovery that cleavage by the ubiquitous enzyme dipeptidyl peptidase-IV (DPP-IV) is the primary route of GLP-1 metabolism formed the rationale behind the proposal to prevent degradation of endogenously released GLP-1 by DPP-IV inhibition as a novel approach to the management of type 2 diabetes. Enhanced insulin secretion as well as delayed gastric emptying, reduced glucagon secretion, and inhibited apoptosis of beta cells resulting from blockade of incretin degradation, have been proposed as the major actions of DPP-IV inhibitors as antidiabetic agents. Clinical studies to date indicate that DPP-IV inhibitors effectively ameliorate islet dysfunction and improve glucose control in patients with type 2 diabetes. They appear to have excellent therapeutic effectiveness as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. Their pharmacokinetic and pharmacodynamic profiles support once-daily dosing, with relatively few adverse effects.
Export Options
About this article
Cite this article as:
Salvatore Teresa, Carbonara Ornella, Cozzolino Domenico, Torella Roberto and Sasso C. Ferdinando, Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors, Current Diabetes Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339909788166819
DOI https://dx.doi.org/10.2174/157339909788166819 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science Towards Improved Therapeutic CORMs: Understanding the Reactivity of CORM-3 with Proteins
Current Medicinal Chemistry Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Vitamin D: Status, Supplementation and Immunomodulation
Current Nutrition & Food Science Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Peptidyl Arginine Deiminases and Neurodegenerative Diseases
Current Medicinal Chemistry Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform
Current Radiopharmaceuticals The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis
Current Pharmaceutical Design Mosquito and Tick-borne Illnesses in the United States. Guidelines for the Recognition and Empiric Treatment of Zoonotic Diseases in the Wilderness.
Infectious Disorders - Drug Targets Synthesis of Drugs and Biorelevant N-heterocycles Employing Recent Advances in C-N Bond Formation
Current Organic Chemistry